News | January 30, 2026
Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
GlideTech materials are available in several standard base resins and offer customization options for specific applications
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Subscribe To Our Newsletter & Stay Updated
